This CPB is revised to state that bortezomib for multiple myeloma is considered medically necessary for the following indications: 1) primary chemotherapy for active (symptomatic) myeloma or for relapse after 6 months following primary therapy with the same regimen in combination with dexamethasone with or without cyclophosphamide, doxorubicin, or lenalidomide for transplant candidates (combination with thalidomide has been removed from medically necessary options); 2) in combination with dexamethasone with or without cyclophosphamide or lenalidomide for nontransplant candidates (combination with MPB has been removed from medically necessary options). Use of bortezomib in combination with prednisone or thalidomide for maintenance therapy has been removed from medically necessary options. This CPB is revised to state that bortezomib for relapsed or progressive or refractory disease is considered medically necessary: 1) in combination with dexamethasone with or without lenalidomide, cyclophosphamide, or daratumumab (combination with thalidomide has been removed from medically necessary options) or with dexamethasone and bendamustine; 2) in combination with elotuzumab and dexamethasone for persons who have received one to three prior therapies; 3) in combination with pomalidomide and dexamethasone for persons who have received at least two prior therapies, including an immunomodulatory agent and a proteasome inhibitor, and have demonstrated disease progression on or within 60 days of completion of the last therapy (preferred). Use of bortezomib as a single agent or in combination with vorinostat have been removed from medically necessary options for relapsed, progressive or refractory disease. This CPB is revised to state that bortezomib is considered experimental and investigational for solitary plasmacytoma or smoldering (asymptomatic) myeloma.